JB/CALL/COSMO PHARMACEUTICALS/55/0.05/21.06.24 Share Price

Warrant

COPCJB

CH1259711120

Market Closed - Swiss Exchange 08:50:00 10/05/2024 pm IST
0.803 CHF -3.37% Intraday chart for JB/CALL/COSMO PHARMACEUTICALS/55/0.05/21.06.24
Current month-12.34%
1 month+1.77%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change Volume
10/24/10 0.803 -3.37% 0
08/24/08 0.831 -4.26% 0
07/24/07 0.868 -2.58% 0
06/24/06 0.891 +1.95% 0
03/24/03 0.874 +3.07% 0

Delayed Quote Swiss Exchange

Last update May 10, 2024 at 08:50 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying COSMO PHARMACEUTICALS N.V.
Issuer Bank Julius Bär
COPCJB
ISINCH1259711120
Date issued 13/04/2023
Strike 55 CHF
Maturity 21/06/2024 (42 Days)
Parity 20 : 1
Emission price 0.39 CHF
Emission volume N/A
Settlement les deux
Currency CHF

Technical Indicators

Highest since issue 1.031 CHF
Lowest since issue 0.012 CHF
Delta0.92x
Omega 4.084
Premium0.23x
Gearing4.44x
Moneyness 1.287
Difference Strike -15.8 CHF
Difference Strike %-28.73%
Spread 0.01 CHF
Spread %1.25%
Theoretical value 0.7980
Implied Volatility 68.38 %
Total Loss Probability 19.59 %
Intrinsic value 0.7900
Present value 0.008000
Break even 70.96 CHF
Theta-0x
Vega0x
Rho0x

Company Profile

Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
Sector
-
More about the company

Ratings for Cosmo Pharmaceuticals N.V.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Consensus: Cosmo Pharmaceuticals N.V.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
72.5 EUR
Average target price
94.95 EUR
Spread / Average Target
+30.98%
Consensus
  1. Stock Market
  2. Warrants
  3. COPCJB Warrant
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW